A multi-component health supplement for improving overall wellness and modulating the immune system is provided as a mixture of N-acetyl-L-cysteine (NAC), quercetin, bromelain, Cordyceps, turmeric extract (curcumin), palmitoylethanolamide (PEA), grape seed extract, green tea extract, elderberry extract, pomegranate extract, and astaxanthin, and optionally one or more vitamins and minerals. Various subcombinations for targeting cellular health, fatigue, oxidative degradation, and other specific health needs are also provided.

Disclosed is a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. This transdermal absorptive liquid formulation has a mode of particle diameter at around 100 nm, and an average particle size of 50 to 500 nm. This transdermal absorptive liquid formulation makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.

N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of autism spectrum disorder and other depressive syndromes. In particular, N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of diseases having decreased endogenous levels of allopregnanolone.

N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of autism spectrum disorder and other depressive syndromes. In particular, N-palmitoylethanolamide (PEA) is used in combination with docosahexaenoic acid (DHA) in the treatment of diseases having decreased endogenous levels of allopregnanolone.

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.

The present invention relates to novel “reverse amide” compounds comprising a zinc chelator group, and the use of such compounds in the inhibition of HDAC6 and in the treatment of various diseases, disorders or conditions related to HDAC6.

The present invention relates to a process of producing a nano-CBD microemulsion system includes: (i) preparing a dispersal phase by dissolving CBD in an ethanol solvent in a ratio between mass of CBD:volumn of ethanol solvent as 8:10 at a speed of 300 to 500 rpm with heating to a temperature ranging from 40 to 60° C. within 4 to 8 hours; (ii) preparing a carrier by heating a liquid PEG (polyethylene glycol) accounted for 40-60% by mass of the mixture of PEG and water to a temperature from 60 to 80° C., stirring homogeneously; (iii) adding the carrier to the dispersal phase in a ratio by mass of 40:60, continuing heating the dispersal phase to a temperature of 40 to 60° C., stirring at a speed of 400 to 800 rpm; (iv) elmusifying as follows: when the temperature arrives at 100° C., adding ACRYSOL K-140 to the mixture of the carrier and dispersal phase obtained in step (iii) in a ratio by mass of 40:60, continuing to stir at a speed of 500 to 700 rpm, at a temperature of about 100° C., in vacuum, the reaction temperature is kept at 100° C. for 3 to 5 hours, controlling the quality of resulting products until it is transparent, the reaction is quenched, the temperature is decreased slowly until it is in the range of 40 to 60° C.; emulsifing the entire mixture for 30 minutes, at a speed of 400 to 800 rpm. (v) filtrating the products by injecting through nanofilters before filling-packaging.

The present disclosure relates to methods of treating or preventing various diseases or disorders, such as cardiac fibrosis, aortic fibrosis, pulmonary fibrosis, renal fibrosis, dermal fibrosis, and chronic kidney diseases, using cannabidiol derivatives or compositions thereof.

The present disclosure relates to methods of treating or preventing various diseases or disorders, such as cardiac fibrosis, aortic fibrosis, pulmonary fibrosis, renal fibrosis, dermal fibrosis, and chronic kidney diseases, using cannabidiol derivatives or compositions thereof.

The present invention relates to lyso-diacylglyceryltrimethylhomoserine (lyso- DGTS) or derivatives thereof for use in the treatment of atherosclerotic cardiovascular disease, and further provides particular such lyso-DGTS derivatives.